News

/News
News 2018-05-30T23:41:30+00:00

May 2014

Two Clinical Studies to be Presented at DDW 2014

Redwood City, Calif. – May 2, 2014 – C2 Therapeutics, a privately held company founded to improve treatment of precursors to esophageal cancer, today announced that data from two clinical studies evaluating the therapeutic impact of its Coldplay Cryoballoon Focal Ablation System will be presented at Digestive Disease Week® (DDW®), on May 6th in Chicago, IL.

C2 Therapeutics DDW 2014 Clinical Study Announcement Card.

Click here for full press release.

C2 Therapeutics Announces Excellent Interim Safety and Efficacy Results of Cryoballoon Ablation

C2 Therapeutics, a privately held company founded to improve treatment of precursors to esophageal cancer (Barrett’s Esophagus or BE), today announced excellent interim results for its Coldplay Cryoballoon Focal Ablation System at the Digestive Disease Week (DDW) in Chicago. Data from the study titled, “Clinical evaluation of a new CryoBalloon Focal Ablation System for the elimination of Barrett’s esophagus” were presented in a poster session today by Bas Weusten, MD, Professor of Innovative Gastrointestinal Endoscopy Senior Gastroenterologist, St. Antonius Hospital Nieuwegein, The Netherlands, and trial’s Principal Investigator.

Click here for full release.

August 2013

C2 Therapeutics Receives FDA Clearance

C2 Therapeutics’ Receives FDA Clearance for Next Generation Cryoballoon Ablation System

Redwood City, Calif. – August 22, 2013 – C2 Therapeutics, a privately held company founded to improve treatment of precursors to esophageal cancer (Barrett’s Esophagus), today announced that it received a 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Cryoballoon Focal Ablation System.  This is the company’s second 510(k) clearance and will be working to introduce Cryoballoon ablation in the United States.  nitial Human Experience with a Novel Through-the-scope Cryoballoon Device for Mucosal Ablation …

Click here to see full release.

June 2013

May 2013

April 2012

DDW2012

Initial Human Experience with a Novel Through-the-scope Cryoballoon Device for Mucosal Ablation

The abstract, Initial Human Experience with a Novel Through-the-scope Cryoballoon Device for Mucosal Ablation (1299398) will be presented during the 53rd Annual Meeting of The Society for Surgery of the Ailmentary Tract (SSAT) in conjunction with DDW at the San Diego Convention Center in San Diego, California.

The abstract can be viewed here: http://meetings.ssat.com/abstracts/2012/QS17.cgi

MKTG 1071 REV A